Phase II study of elsamitrucin in non-small cell lung cancer

  title={Phase II study of elsamitrucin in non-small cell lung cancer},
  author={G. Goss and F. Letendre and D. Stewart and F. Shepherd and L. Schacter and P. Hoogendoorn and E. Eisenhauer},
  journal={Investigational New Drugs},
Elsamitrucin (BMY-28090) a novel fermentation product has demonstrated pre-clinical anti-tumour activity against a number of cell lines. The dose limiting toxicity in phase I studies was a reversible increase in hepatic transaminase. This study was initiated to determine the activity of elsamitrucin in patients with previously untreated, bi-dimensionally measurable, cytologically or histologically proven, non-small cell lung cancer who were not curable by surgery. Elsamitrucin at a dose of 25… Expand
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma
Emerging DNA topisomerase inhibitors as anticancer drugs.
  • W. Denny
  • Biology, Medicine
  • Expert opinion on emerging drugs
  • 2004
Emerging DNA topoisomerase inhibitors as anticancer drugs
Structures and biological activities of novel 4’-acetylated analogs of chrysomycins A and B
Anti Cancer: DNA Topoisomerase Inhibitors


Phase I clinical trial of elsamitrucin (abstract
  • Proc Am Assoc Can Res
  • 1990
Phase I study of elsamicin ( BMY28090 ) ( abstract )
  • Proc Am Soc Clin Onc
  • 1990
Phase I/pharmacokinetic study of elsamitrucin (BMY-28090, NSC 369 327) in patients with advanced cancer (abstract
  • Proc Am Soc Clin Onc 9(279):72,
  • 1990